Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.79 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | PTGES | O14684 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.75 |
| ▸ | MTOR | P42345 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181605 | 1.00 | ALOX5AP (0.79) | ALOX5APALOX5CYP3A4CYP2C9KDM4E | |
| SCHEMBL23270814 | 0.92 | ALOX5AP (0.73) | ALOX5APALOX5CYP3A4CYP2C9KDM4E | |
| SCHEMBL30181492 | 0.92 | ALOX5AP (0.73) | ALOX5APALOX5CYP3A4CYP2C9KDM4E | |
| SCHEMBL9044184 | 0.91 | PTGES2 (0.78) | ALOX5APALOX5CYP3A4CYP2C9KDM4E | |
| SCHEMBL169604 | 0.89 | PTGES2 (0.67) | ALOX5APALOX5CYP3A4CYP2C9KDM4E | |
| SCHEMBL30181651 | 0.89 | PTGES2 (0.67) | ALOX5APALOX5CYP3A4CYP2C9KDM4E | |
| SCHEMBL9178392 | 0.88 | ALOX5AP (0.81) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1193380 | 0.88 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9KDM4E | |
| SCHEMBL25968193 | 0.87 | ALOX5AP (0.79) | ALOX5APALOX5CYP3A4CYP2C9KDM4E | |
| SCHEMBL9044519 | 0.87 | ALOX5AP (0.79) | ALOX5APALOX5CYP3A4CYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043423-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| CN-113329996-B | Compounds and methods for treating hedgehog pathway related disorders | 博远医药(苏州)有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-113329996-A | Compounds and methods for treating hedgehog pathway related disorders | 苏州麦迪耐斯医药科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3810573-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | Suzhou Mednes Pharma Tech Co., Ltd. (CN) | 2021-04-28 | — | — | EP | disclosed |
| US-5420282-A | Inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1995-05-30 | — | — | US | disclosed |
| US-5288743-A | Lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| US-5272145-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-12-21 | — | — | US | disclosed |
| US-5254541-A | (Quinolin-2-ylmethoxy)indole/cyclodextrin complex | MERCK FROSST CANADA, INC. (CA) | 1993-10-19 | — | — | US | disclosed |
| US-5254567-A | Antihistamines, antiinflammatory agent, antiallergens, cytoprotective agent | MERCK FROSST CANADA, INC. (CA) | 1993-10-19 | — | — | US | disclosed |
| WO-1993010115-A1 | AMORPHOUS (QUINOLIN-2-YLMETHOXY) INDOLES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-05-27 | — | — | WO | disclosed |
| EP-0542355-A1 | Amorphous (Quinolin-2-ylmethoxy)indoles as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1993-05-19 | — | — | EP | disclosed |
| EP-0542356-A1 | (Quinolin-2-ylmethoxy) indole/cyclodextrin complex as leukotrien inhibitor | MERCK FROSST CANADA INC. (CA) | 1993-05-19 | — | — | EP | disclosed |
| US-5204344-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| EP-0518426-A1 | Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-12-16 | — | — | EP | disclosed |
| EP-0419049-A1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SHH, GLI1, SMO | ALOX5AP 3783/4885ALOX5 1983/4885CYP3A4 3134/4885 |
| US-20240043423-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | ALOX5AP 3709/4885ALOX5 1833/4885CYP3A4 2857/4885 |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | ALOX5AP 3783/4885ALOX5 1983/4885CYP3A4 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.